Disclaimer

The website is targeted at investors qualifying as professional investors under MiFID (Directive 2004/39/EU) only. Retail investors are therefore kindly asked to leave this website.

The website and its content is not intended for US Persons, who are kindly asked to leave the website as well.

The content of the website is for information purposes only. The information does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any of the products or services mentioned on the website. The information, calculations etc. on the website shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the information available through the website. However, the correctness and accuracy is not guaranteed and C WorldWide Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions. Neither is C WorldWide Management Fondsmaeglerselskab A/S responsible for the suitability of the information on or the content of the website. The information on the website may be amended by C WorldWide Management Fondsmaeglerselskab A/S at any time without notice.

The website and its content has been prepared in accordance with Danish law and the information provided may not satisfy the laws of any other country.

Past performance is not a reliable indicator of future performance.

By accepting, I confirm that I am a professional investor, and that I have understood the terms of use.

Leave
Accept
ⓒ C WORLDWIDE ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S | DAMPFAERGEVEJ 26 | DK-2100 COPENHAGEN | CVR: 78 42 05 10
Fakta

C WORLDWIDE MEDICAL AS OF 31 MAY 2017

NET OF FEES IN EUR

STRATEGY

The investment objective of the C WorldWide Medical fund is to achieve long-term capital growth through global investment in equities of companies operating in the pharmaceutical, biotechnology and medical technology sectors. The emphasis is on large-cap companies, however a considerable part of the portfolio consists of mid and small-cap companies. These are often more difficult to value and less analyzed than large cap companies.

INVESTMENT RETURNS

89A4CC C WorldWide Medical CDCCCC Benchmark

TOP 10 HOLDINGS

Share in %
Unitedhealth Group 6.8 %
Johnson & Johnson 6.5 %
Gilead Sciences 5.1 %
Roche Hld. 4.8 %
C WorldWide Medical Small & Mid Cap 4.1 %
Actavis 4.1 %
Amgen 4.0 %
Pfizer 4.0 %
Novartis Holding 3.9 %
Merck & Co 3.8 %

RETURN & RISK

1 Y 3 Y 5 Y 10 Y Lifetime P.A.
C WorldWide Medical (%) -0.2 7.4 13.6 6.1 8.6 8.6
Benchmark (%) 6.7 14.1 17.9 10.0 6.2 6.2
Relative performance (%) -6.9 -6.6 -4.3 -3.9 2.4 2.4
3 Y 5 Y 10 Y Lifetime P.A.
Std. dev. portfolio (%) 19.0 16.5 15.2 17.9 17.9
Std. dev. benchmark (%) 15.0 12.8 13.0 13.4 13.4
Beta 1.2 1.2 1.1 0.9 0.9

GEOGRAPHIC DIVERSIFICATION

SECTOR EXPOSURE

FACTS

Security identifier (ISIN): LU0090908194
Launch date: 15 December 1998
Management fee: 1.70% per annum
Dealing frequency: Daily
Base currency: EUR
Minimum investment: EUR 1,000
Benchmark: MSCI World Healthcare Index
NAV at month end: 92.26
Fund AUM: 549.5 million
Investment Manager: C WorldWide Asset Management, Stockholm
Portfolio Manager: Angelica Fatouros

DISCLAIMER

The fact sheet is for information purposes only. The fact sheet does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any fund. The information, calculations etc. shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the fact sheet. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions.

It is emphasized that the figures in the fact sheet are historical, and that past performance is no reliable indicator of future performance.